Top in endocrinology: Tirzepatide vs. semaglutide; FDA rejects icodec for diabetes
Click Here to Manage Email Alerts
Researchers found that adults with overweight or obesity lost more weight with tirzepatide than semaglutide in a head-to-head comparison of the medications using electronic medical records data.
Results showed that a weight loss of 15% or higher was achieved by 42.3% of the tirzepatide group vs. 18.1% of the semaglutide group.
“This is the first study to compare the effectiveness of these medications directly in real-world populations with overweight or obesity,” Patricia J. Rodriguez, PhD, MPH, principal applied scientist at Truveta Research, told Healio.
It was the top story in endocrinology last week.
In another top story, the FDA rejected once-weekly basal insulin icodec for the treatment of diabetes and is requesting more information on the manufacturing process and the type 1 diabetes indication from Novo Nordisk.
Read these and more top stories in endocrinology below:
Tirzepatide led to greater real-world weight loss than semaglutide for adults with obesity
Adults with overweight or obesity lost more weight with the GIP/GLP-1 dual agonist tirzepatide than the GLP-1 receptor agonist semaglutide, according to findings published in JAMA Internal Medicine. Read more.
FDA rejects once-weekly basal insulin for diabetes, requests more information
The FDA declined to approve once-weekly basal insulin icodec for the treatment of diabetes and is requesting more information from Novo Nordisk, according to a company press release. Read more.
Combined SGLT2 and GLP-1 therapy lowers risk for CVD, kidney disease in type 2 diabetes
Combined SGLT2 inhibitor and GLP-1 receptor agonist therapy could provide additional cardiovascular and renal benefits for adults with type 2 diabetes, according to data from a meta-analysis published in The Lancet Diabetes & Endocrinology. Read more.
More than 20% of US adults with type 1 diabetes likely have chronic kidney disease
More than one in five adults in the United States with type 1 diabetes also have chronic kidney disease, according to findings from a brief report published in Diabetes Care. Read more.
AI model highly accurate in determining malignancy of thyroid nodule images
An AI model achieved higher accuracy than three cytopathologists for determining malignancy in a large dataset of image patches of thyroid fine-needle aspiration whole-slide images, according to a study published in Thyroid. Read more.